Skip to content

US · BIAFW · MEDICAL - SPECIALTIES

bioAffinity Technologies, Inc. (BIAFW) intrinsic value and stock valuation

$0.16as of 2026-11-21 · Mkt cap 2.49M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

bioAffinity Technologies, Inc. DCF and intrinsic value

InvestorsCraft values BIAFW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BIAFW’s statements →

bioAffinity Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties San Antonio, TX 78217 bioaffinitytech.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$6.16M
20192025
Net income
-$-14.91M
20192025
Free cash flow
-$-9.39M
20192025
Total equity
$7.28M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$6.16M$9.36M$2.53M$0.00$0.00
Operating income-$-10.57M-$-8.95M-$-7.97M-$-4.01M-$-2.21M
Net income-$-14.91M-$-9.04M-$-7.94M-$-8.15M-$-6.33M
EPSd-$-8.67M-$-22.6M-$-27.38M-$-54.33M-$-70.33M
Operating cash flow-$-9.33M-$-7.26M-$-6.04M-$-4.07M-$-2.05M
Capital expenditure-$-60K-$-80K-$-20K-$-220K-$0.00
Free cash flow-$-9.39M-$-7.34M-$-6.06M-$-4.29M-$-2.05M
Total assets$11M$6.51M$8.22M$12.2M$1.45M
Total debt$1.16M$1.5M$1.58M$250K$11.4M
Net debt-$-5.29M$400K-$-1.24M-$-11.16M$10M
Total equity$7.28M$2.6M$4.86M$11M-$-15.79M
Cash and short-term investments$6.45M$1.11M$2.82M$11.4M$1.36M
Income statement
20252024202320222021
Revenue$6.16M$9.36M$2.53M$0.00$0.00
Cost of revenue$4.73M$5.98M$1.74M$0.00$0.00
Gross profit$1.43M$3.38M$790K$0.00-$0.00
Research and development expenses$2.09M$1.78M$1.73M$1.52M$1.14M
Selling, general and administrative expenses$9.91M$9.94M$6.79M$2.48M$1.07M
Other expenses$0.00$610K$250K$10K$0.00
Operating expenses$12M$12.3M$8.77M$4.02M$2.2M
Cost and expenses$16.7M$18.3M$10.5M$4.02M$2.21M
Interest income$20K$20K$120K$50K$0.00
Interest expense$40K$90K$40K$2.53M$1M
Depreciation and amortization$500K$610K$250K$10K$0.00
Ebitda-$-14.32M-$-8.33M-$-7.63M-$-5.61M-$-5.32M
Operating income-$-10.57M-$-8.95M-$-7.97M-$-4.01M-$-2.21M
Total other income/expenses, net-$-4.29M-$-80K$60K-$-4.14M-$-4.12M
Income before tax-$-14.87M-$-9.03M-$-7.92M-$-8.15M-$-6.32M
Income tax expense$40K$10K$20K$0.00$0.00
Net income-$-14.91M-$-9.04M-$-7.94M-$-8.15M-$-6.33M
Weighted average shares outstanding$1.72M$400K$290K$150K$90K
Weighted average diluted shares outstanding$1.72M$400K$290K$150K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$6.45M$1.11M$2.82M$11.4M$1.36M
Net receivables$540K$1.14M$810K$10K$0.00
Inventory$50K$30K$20K$10K$0.00
Total current assets$7.57M$2.7M$3.97M$12M$1.44M
Property, plant and equipment, net$1.26M$1.62M$1.99M$210K$0.00
Goodwill and intangible assets$2.12M$2.18M$2.24M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.4M$3.82M$4.25M$220K$20K
Total assets$11M$6.51M$8.22M$12.2M$1.45M
Accounts payable$760K$990K$600K$350K$230K
Short-term debt$380K$690K$920K$250K$11.2M
Deferred revenue$40K$20K$30K$0.00$0.00
Total current liabilities$2.91M$3.1M$2.25M$1.14M$13M
Long-term debt$780K$810K$1.12M$0.00$160K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$780K$810K$1.12M$0.00$4.2M
Capital lease obligations$740K$1.31M$1.58M$0.00$0.00
Total liabilities$3.68M$3.91M$3.37M$1.14M$17.2M
Common stock$30K$110K$70K$60K$20K
Retained earnings-$-68.55M-$-53.64M-$-44.6M-$-36.67M-$-28.51M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-4.04M
Total equity$7.28M$2.6M$4.86M$11M-$-15.79M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.16M$1.5M$1.58M$250K$11.4M
Net debt-$-5.29M$400K-$-1.24M-$-11.16M$10M
Cash flow statement
20252024202320222021
Net income-$-14.91M-$-9.04M-$-7.94M-$-8.15M-$-6.33M
Depreciation and amortization$500K$610K$250K$10K$0.00
Stock-based compensation$670K$990K$750K$250K$40K
Change in working capital$590K$180K$900K$110K$630K
Accounts receivable$600K-$-330K$310K-$-10K$0.00
Inventory-$-30K-$-10K-$-10K-$-10K$0.00
Accounts payable-$-230K$380K-$-10K$110K$40K
Net cash provided by operating activities-$-9.33M-$-7.26M-$-6.04M-$-4.07M-$-2.05M
Investments in property, plant and equipment-$-60K-$-80K-$-20K-$-220K$0.00
Acquisitions, net$0.00$0.00-$-2.19M$0.00$0.00
Net cash used for investing activities-$-60K-$-80K-$-2.21M-$-220K$0.00
Common stock issued$15.1M$4.35M$0.00$6.03M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.7M$5.63M-$-340K$14.3M$3.33M
Net change in cash$5.34M-$-1.72M-$-8.59M$10.1M$1.28M
Cash at end of period$6.45M$1.11M$2.82M$11.4M$1.36M
Operating cash flow-$-9.33M-$-7.26M-$-6.04M-$-4.07M-$-2.05M
Capital expenditure-$-60K-$-80K-$-20K-$-220K-$0.00
Free cash flow-$-9.39M-$-7.34M-$-6.06M-$-4.29M-$-2.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About bioAffinity Technologies, Inc.

        bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

        CEO
        Maria Zannes
        Employees
        57
        Beta
        -1.05

        Explore

        Frequently asked questions

        What is the intrinsic value of bioAffinity Technologies, Inc. (BIAFW)?

        InvestorsCraft does not currently publish an intrinsic value for BIAFW. How the IC value is calculated.

        Is BIAFW undervalued?

        InvestorsCraft does not publish an undervaluation signal for BIAFW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.